Bayer Cipro
Executive Summary
FDA's Anti-Infective Drugs Advisory Committee will consider ciprofloxacin sNDAs July 28 for the post-exposure prophylaxis of clinical disease from inhaled bacillus anthracis (anthrax). The meeting will be held at FDA's Parklawn building, starting at 8:30 a.m